We are live on ! Find out more
MRNS

Marinus Pharmaceuticals, Inc

Delisted

MRNS was delisted on the 10th of February, 2025.

23 hedge funds and large institutions have $4.9M invested in Marinus Pharmaceuticals, Inc in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

12% less funds holding

Funds holding: 2623 (-3)

56% less capital invested

Capital invested by funds: $11M → $4.9M (-$6.12M)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
23
Holders Change
-3
Holders Change %
-11.54%
% of All Funds
0.57%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
8
Reduced
4
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
TSS
26
Two Sigma Securities
New York
-$29K -3,924 Closed
Bank of America
27
Bank of America
North Carolina
-$1K -138 Closed

MRNS Hedge Fund Activity: Q4 2016 in Review

23 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q4 2016, worth a combined $4.9M — down 56% from $11M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of MRNS and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 8 added.

The largest buyer was BlackRock Institutional Trust, adding an estimated $109K. The largest seller was ArrowMark Colorado Holdings, exiting entirely with an estimated $1.72M sold.

  • 23 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q4 2016, down from 26 in Q3 2016.
  • Funds reported $4.9M of Marinus Pharmaceuticals, Inc stock for Q4 2016, down 56% quarter-over-quarter.
  • 2 funds opened new Marinus Pharmaceuticals, Inc positions in Q4 2016 and 5 closed out, a net change of -3 holders.
  • The largest Marinus Pharmaceuticals, Inc buyer in Q4 2016 was BlackRock Institutional Trust, an estimated $109K added.
  • The largest Marinus Pharmaceuticals, Inc seller in Q4 2016 was ArrowMark Colorado Holdings, an estimated $1.72M sold.

Based on aggregated 13F filings for Q4 2016.